Results 81 to 90 of about 23,326 (221)

Dupilumab-Associated Blepharoconjunctivitis with Giant Papillae

open access: yesInternational Medical Case Reports Journal, 2020
Filippos Vingopoulos, Douglas R Lazzaro New York University School of Medicine, Department of Ophthalmology, New York, NY 10017, USACorrespondence: Douglas R LazzaroNew York University School of Medicine, Department of Ophthalmology, 222 East 41st Street,
Vingopoulos F, Lazzaro DR
doaj  

Mepolizumab versus placebo for asthma [PDF]

open access: yes, 2015
Background Mepolizumab is a human monoclonal antibody against interleukin-5 (IL-5), the main cytokine involved in the activation of eosinophils, which in turn causes airway inflammation.
Alvarez-Cuesta   +149 more
core   +2 more sources

Multi-ancestry genome-wide association study of 21,000 cases and 95,000 controls identifies new risk loci for atopic dermatitis [PDF]

open access: yes, 2015
Genetic association studies have identified 21 loci associated with atopic dermatitis risk predominantly in populations of European ancestry. To identify further susceptibility loci for this common, complex skin disease, we performed a meta-analysis of ...
(AAGC), Australian Asthma Genetics Consortium   +152 more
core   +6 more sources

41817 Dupilumab Treatment Improves Sleep Quality in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis and Their Caregivers [PDF]

open access: bronze, 2023
Amy S. Paller   +9 more
openalex   +1 more source

Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab [PDF]

open access: bronze, 2020
Erminia Ridolo   +6 more
openalex   +1 more source

44290 Case of vitiligo after initiation of dupilumab therapy [PDF]

open access: bronze, 2023
Elnara Muradova   +4 more
openalex   +1 more source

Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme [PDF]

open access: yes, 2015
BACKGROUND : The most prevalent phenotype of asthma is characterized by eosinophil-dominated inflammation that is driven by a type 2 helper T cell (Th2).
Bachert, Claus   +20 more
core   +2 more sources

Dupilumab – a novel treatment option against allergic diseases: a state-of-the-art review

open access: yesAlergologia Polska
Dupilumab is a humanized, IgG4 monoclonal antibody which binds to the α subunit of interleukin 4 receptor (IL-4R) and interleukin 13 receptor (IL-13R), thereby it inhibits their action.
Klaudia Kołakowska, Maciej Czubek
doaj   +1 more source

Attenuating the atopic march: Meta-analysis of the dupilumab atopic dermatitis database for incident allergic events [PDF]

open access: bronze, 2022
Gregory P. Geba   +6 more
openalex   +1 more source

Home - About - Disclaimer - Privacy